Review

Ribosome-inactivating proteins with an emphasis on bacterial RIPs and their potential medical applications

Departamento de Biotecnología, División de Ciencias Biológicas & de la Salud, Universidad Autónoma Metropolitana, Mexico City, Mexico

Química Agronómica de México, Calle 18 No. 20501, Parque Industrial Impulso C.P 31109, Chihuahua, Chihuahua, México

Search for more papers by this author

Jozef Anné

Laboratory of Bacteriology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

Search for more papers by this author

Armando Mejía

* Author for correspondence

Departamento de Biotecnología, División de Ciencias Biológicas & de la Salud, Universidad Autónoma Metropolitana, Mexico City, Mexico.

Search for more papers by this author

Email the corresponding author at ama@xanum.uam.mx

Published Online:18 Jun 2012https://doi.org/10.2217/fmb.12.39

View article

Abstract

Ribosome-inactivating proteins (RIPs) are toxic due to their N-glycosidase activity catalyzing depurination at the universally conserved α-sarcin loop of the 60S ribosomal subunit. In addition, RIPs have been shown to also have other enzymatic activities, including polynucleotide:adenosine glycosidase activity. RIPs are mainly produced by different plant species, but are additionally found in a number of bacteria, fungi, algae and some mammalian tissues. This review describes the occurrence of RIPs, with special emphasis on bacterial RIPs, including the Shiga toxin and RIP in Streptomyces coelicolor recently identified in S. coelicolor. The properties of RIPs, such as enzymatic activity and targeting specificity, and how their unique biological activity could be potentially turned into medical or agricultural tools to combat tumors, viruses and fungi, are highlighted.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Barbieri L, Valbonesi P, Bondioli M et al. Adenine glycosylase activity in mammalian tissues: an equivalent of ribosome-inactivating proteins. FEBS Lett.505(1),196–197 (2001).Crossref, Medline, CAS, Google Scholar
2 Stirpe F. Ribosome-inactivating proteins. Toxicon44(4),371–383 (2004).▪▪ Interesting overview of the state of the art regarding ribosome-inactivating proteins (RIPs).Crossref, Medline, CAS, Google Scholar
3 Olsnes S, Pihl A. Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis. Biochemistry12(16),3121–3126 (1973).Crossref, Medline, CAS, Google Scholar
4 Reinbothe S, Reinbothe C, Lehmann J, Becker W, Apel K, Parthier B. JIP60, a methyl jasmonate-induced ribosome-inactivating protein involved in plant stress reactions. Proc. Natl Acad. Sci. USA91(15),7012–7016 (1994).Crossref, Medline, CAS, Google Scholar
5 Walsh TA, Morgan AE, Hey TD. Characterization and molecular cloning of a proenzyme form of a ribosome-inactivating protein from maize. Novel mechanism of proenzyme activation by proteolytic removal of a 2.8-kilodalton internal peptide segment. J. Biol. Chem.266(34),23422–23427 (1991).Crossref, Medline, CAS, Google Scholar
6 Motto M, Lupotto E. The genetics and properties of cereal ribosome-inactivating proteins. Mini Rev. Med. Chem.4(5),493–503 (2004).Crossref, Medline, CAS, Google Scholar
7 Peumans WJ, Hao Q, Van Damme EJ. Ribosome-inactivating proteins from plants: more than RNA N-glycosidases? FASEB J.15(9),1493–1506 (2001).Crossref, Medline, CAS, Google Scholar
8 Girbes T, Citores L, Ferreras JM et al. Isolation and partial characterization of nigrin b, a non-toxic novel type 2 ribosome-inactivating protein from the bark of Sambucus nigra L. Plant Mol. Biol.22(6),1181–1186 (1993).Crossref, Medline, CAS, Google Scholar
9 Sandvig K, Olsnes S, Pihl A. Kinetics of binding of the toxic lectins abrin and ricin to surface receptors of human cells. J. Biol. Chem.251(13),3977–3984 (1976).Crossref, Medline, CAS, Google Scholar
10 Barbieri L, Battelli MG, Stirpe F. Ribosome-inactivating proteins from plants. Biochim. Biophys. Acta1154(3–4),237–282 (1993).Crossref, Medline, CAS, Google Scholar
11 de Virgilio M, Lombardi A, Caliandro R, Fabbrini MS. Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins2,2699–2737 (2010).▪ Interesting discussion on successful designs and features of chimeric molecules having therapeutic potential.Crossref, Medline, CAS, Google Scholar
12 Park SW, Vepachedu R, Sharma N, Vivanco JM. Ribosome-inactivating proteins in plant biology. Planta219(6),1093–1096 (2004).Crossref, Medline, CAS, Google Scholar
13 Brigotti M, Alfieri R, Sestili P et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J.16(3),365–372 (2002).Crossref, Medline, CAS, Google Scholar
14 Tesh VL. The induction of apoptosis by shiga toxins and ricin. Curr. Top. Microbiol. Immunol.357,137–178 (2012).▪▪ Overview of studies describing Shiga toxin- and ricin-induced apoptosis, and evidence that signaling through the ribotoxic stress response and the unfolded protein response may be involved in apoptosis induction in some cell types.Crossref, Medline, Google Scholar
15 Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J. Biol. Chem.255(14),6947–6953 (1980).Crossref, Medline, CAS, Google Scholar
16 Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res.10(2),415–427 (2004).Crossref, Medline, Google Scholar
17 Thiesen HJ, Juhl H, Arndt R. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Res.47(2),419–423 (1987).Medline, CAS, Google Scholar
18 Parikh BA, Tumer NE. Antiviral activity of ribosome inactivating proteins in medicine. Mini Rev. Med. Chem.4(5),523–543 (2004).Crossref, Medline, CAS, Google Scholar
19 Puri M, Kaur I, Kanwar RK, Gupta RC, Chauhan A, Kanwar JR. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy. Curr. Mol. Med.9(9),1080–1094 (2009).Crossref, Medline, CAS, Google Scholar
20 Pang YP, Park JG, Wang S et al. Small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach. PLoS One6(3),e17883 (2011).Crossref, Medline, CAS, Google Scholar
21 Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem.262(12),5908–5912 (1987).Crossref, Medline, CAS, Google Scholar
22 Barbieri L, Gorini P, Valbonesi P, Castiglioni P, Stirpe F. Unexpected activity of saporins. Nature372(6507),624 (1994).Crossref, Medline, CAS, Google Scholar
23 Barbieri L, Valbonesi P, Bonora E, Gorini P, Bolognesi A, Stirpe F Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). Nucleic Acids Res.25(3),518–522 (1997).Crossref, Medline, CAS, Google Scholar
24 Endo Y, Gluck A, Wool IG. Ribosomal RNA identity elements for ricin A-chain recognition and catalysis. J. Mol. Biol.221(1),193–207 (1991).Crossref, Medline, CAS, Google Scholar
25 Hudak KA, Wang P, Tumer NE. A novel mechanism for inhibition of translation by pokeweed antiviral protein: depurination of the capped RNA template. RNA6(3),369–380 (2000).Crossref, Medline, CAS, Google Scholar
26 Gessner SL, Irvin JD. Inhibition of elongation factor 2-dependent translocation by the pokeweed antiviral protein and ricin. J. Biol. Chem.255(8),3251–3253 (1980).Crossref, Medline, CAS, Google Scholar
27 Irvin JD. Pokeweed antiviral protein. Pharmacol. Ther.21(3),371–387 (1983).Crossref, Medline, CAS, Google Scholar
28 Holmberg L, Nygard O. Interaction sites of ribosome-bound eukaryotic elongation factor 2 in 18S and 28S rRNA. Biochemistry33(50),15159–15167 (1994).Crossref, Medline, CAS, Google Scholar
29 Alegre C, Iglesias R, Ferreras JM, Citores L, Girbes T. Sensitivity of ribosomes from Agrobacterium tumefaciens to the ribosome-inactivating protein crotin 2 depending on the translocational state. Cell Mol. Biol.42(2),151–158 (1996).Medline, CAS, Google Scholar
30 Wang P, Tumer NE. Virus resistance mediated by ribosome inactivating proteins. Adv. Virus Res.55,325–355 (2000).Crossref, Medline, CAS, Google Scholar
31 Li XP, Chiou JC, Remacha M, Ballesta JP, Tumer NE. A two-step binding model proposed for the electrostatic interactions of ricin A chain with ribosomes. Biochemistry48(18),3853–3863 (2009).Crossref, Medline, CAS, Google Scholar
32 Zamboni M, Brigotti M, Rambelli F, Montanaro L, Sperti S. High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem. J.259(3),639–643 (1989).Crossref, Medline, CAS, Google Scholar
33 Rajamohan F, Kurinov IV, Venkatachalam TK, Uckun FM. Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. Biochem. Biophys. Res. Commun.263(2),419–424 (1999).Crossref, Medline, CAS, Google Scholar
34 Shih NR, McDonald KA, Jackman AP, Girbés T, Iglesias R. Bifunctional plant defence enzymes with chitinase and ribosome inactivating activities from Trichosanthes kirilowii cell cultures. Plant Sci.130(2),145–150 (1997).Crossref, CAS, Google Scholar
35 Helmy M, Lombard S, Pieroni G. Ricin RCA60: evidence of its phospholipase activity. Biochem. Biophys. Res. Commun.258(2),252–255 (1999).Crossref, Medline, CAS, Google Scholar
36 Chen H, Wang Y, Yan MG, Yu MK, Yao QZ. The phosphatase activity of five ribosome-inactivating proteins. Chin. Biochem. J.12,125–129 (1996).CAS, Google Scholar
37 Day PJ, Lord JM, Roberts LM. The deoxyribonuclease activity attributed to ribosome-inactivating proteins is due to contamination. Eur. J. Biochem.258(2),540–545 (1998).Crossref, Medline, CAS, Google Scholar
38 Wang HX, Ng TB, Cheng CH et al. Contamination of ribosome inactivating proteins with ribonucleases, separated by affinity chromatography on red sepharose. Prep. Biochem. Biotechnol.33(2),101–111 (2003).Crossref, Medline, CAS, Google Scholar
39 Girbés T, Ferreras JM, Arias FJ, Stirpe F. Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev. Med. Chem.4(5),461–476 (2004).Crossref, Medline, CAS, Google Scholar
40 Narayanan S, Surendranath K, Bora N, Surolia A, Karande AA. Ribosome inactivating proteins and apoptosis. FEBS Lett.579(6),1324–1331 (2005).Crossref, Medline, CAS, Google Scholar
41 Stirpe F, Battelli MG. Ribosome-inactivating proteins: progress and problems. Cell. Mol. Life Sci.63(16),1850–1866 (2006).Crossref, Medline, CAS, Google Scholar
42 Ishizaki T, Megumi C, Komai F, Masuda K, Oosawa K. Accumulation of a 31-kDa glycoprotein in association with the expression of embryogenic potential by spinach callus in culture. Physiol. Plant114(1),109–115(2002).Crossref, Medline, CAS, Google Scholar
43 Barbieri L, Polito L, Bolognesi A et al. Ribosome-inactivating proteins in edible plants and purification and characterization of a new ribosome-inactivating protein from Cucurbita moschata. Biochim. Biophys. Acta1760(5),783–792 (2006).Crossref, Medline, CAS, Google Scholar
44 Ferreras JM, Citores L, de Benito FM et al. Ribosome-inactivating proteins and lectins from Sambucus. Curr. Top. Phytochem.3,113–128 (2000).CAS, Google Scholar
45 Ling J, Liu WY, Wang TP. Simultaneous existence of two types of ribosome-inactivating proteins in the seeds of Cinnamonum camphora – characterization of the enzymatic activities of these cytotoxic proteins. Biochim. Biophys. Acta1252(1),15–22 (1995).Crossref, Medline, Google Scholar
46 Van Damme EJ, Barre A, Barbieri L et al. Type 1 ribosome-inactivating proteins are the most abundant proteins in iris (Iris hollandica var. Professor Blaauw) bulbs: characterization and molecular cloning. Biochem. J.324(3),963–970 (1997).Crossref, Medline, CAS, Google Scholar
47 Peumans WJ, Van Damme EJM. Evolution of plant ribosome-inactivating proteins. In: Toxic Plant Proteins. Plant Cell Monographs 18. Lord JM, Hartley MR (Eds). Springer-Verlag, Berlin Heidelberg, Germany, 1–26 (2010).▪▪ Interesting analysis of the evolution of RIPs in plants from the ancestral type 1 RIP to modern type 2 RIPs.Google Scholar
48 Reisbig R, Olsnes S, Eiklid K. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. J. Biol. Chem.256(16),8739–8744 (1981).Crossref, Medline, CAS, Google Scholar
49 Obrig TG. Shiga toxin mode of action in E. coli O157:H7 disease. Front. Biosci.2,d635–d642 (1997).Crossref, Medline, CAS, Google Scholar
50 Reyes AG, Geukens N, Gutschoven P et al. The Streptomyces coelicolor genome encodes a type I ribosome-inactivating protein. Microbiology156(10),3021–3030 (2010).Crossref, Medline, CAS, Google Scholar
51 Ng TB, Parkash A. Hispin, a novel ribosome inactivating protein with antifungal activity from hairy melon seeds. Protein Expr. Purif.26(2),211–217 (2002).Crossref, Medline, CAS, Google Scholar
52 Wang H, Ng TB. Isolation and characterization of velutin, a novel low-molecular-weight ribosome-inactivating protein from winter mushroom (Flammulina velutipes) fruiting bodies. Life Sci.68(18),2151–2158 (2001).Crossref, Medline, CAS, Google Scholar
53 Wang HX, Ng TB. Flammulin: a novel ribosome-inactivating protein from fruiting bodies of the winter mushroom Flammulina velutipes. Biochem. Cell Biol.78(6),699–702 (2000).Crossref, Medline, CAS, Google Scholar
54 Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol. Rev.76(4),949–966 (1996).Crossref, Medline, CAS, Google Scholar
55 Sandvig K. Shiga toxins. Toxicon39(11),1629–1635 (2001).Crossref, Medline, CAS, Google Scholar
56 Gyles CL. Shiga toxin-producing Escherichia coli: an overview. J. Anim. Sci.85(13 Suppl.),E45–E62 (2007).Crossref, Medline, CAS, Google Scholar
57 Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev.11(3),450–479 (1998).Crossref, Medline, CAS, Google Scholar
58 Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr. Opin. Cell Biol.12(4),407–413 (2000).Crossref, Medline, CAS, Google Scholar
59 Johannes L, Romer W. Shiga toxins – from cell biology to biomedical applications. Nat. Rev. Microbiol.8(2),105–116 (2010).▪▪ Reviews the Shiga toxin family members and their structures, receptors, trafficking pathways and cellular targets, and how Shiga toxin affects cells and might be exploited in cancer therapy and immunotherapy.Crossref, Medline, CAS, Google Scholar
60 Ferens WA, Hovde CJ. Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation. Infect. Immun.68(8),4462–4469 (2000).Crossref, Medline, CAS, Google Scholar
61 Jones NL, Islur A, Haq R et al.Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol.278(5),G811–G819 (2000).Crossref, Medline, CAS, Google Scholar
62 Jandhyala DM, Thorpe CM, Magun B. Ricin and shiga toxins: effects on host cell signal transduction. Curr. Top. Microbiol. Immunol.357,1–65 (2012).Medline, Google Scholar
63 Das MK, Sharma RS, Mishra V. Induction of apoptosis by ribosome inactivating proteins: importance of N-glycosidase activity. Appl. Biochem. Biotechnol.166(6),1552–1561 (2012).▪ Reviews various experimental outcomes on the importance of N-glycosidase activity of RIPs in the induction of apoptosis.Crossref, Medline, CAS, Google Scholar
64 Hotz B, Backer MV, Backer JM, Buhr HJ, Hotz HG. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia12(10),797–806 (2010).▪ Results show that Shiga-like toxin–VEGF fusion protein treatment in combination with gemcitabine may provide a novel approach for pancreatic cancer.Crossref, Medline, CAS, Google Scholar
65 Falguieres T, Mallard F, Baron C et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell12(8),2453–2468 (2001).Crossref, Medline, CAS, Google Scholar
66 Polito L, Bortolotti M, Pedrazzi M, Bolognesi A. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. Toxins (Basel)3(6),697–720 (2011).Crossref, Medline, CAS, Google Scholar
67 Lingwood CA. Shiga toxin receptor glycolipid binding. Pathology and utility. Methods Mol. Med.73,165–186 (2003).Medline, CAS, Google Scholar
68 Cheung MC, Revers L, Perampalam S et al. An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo. Mol. Cancer9,28 (2010).▪▪ Interesting report on the discovery and properties of a single chain RIP derived from the cytotoxic A-subunit of SLT-1 demonstrating that evolution of a single chain RIP template can lead to the discovery of novel cancer cell-targeted compounds.Crossref, Medline, Google Scholar
69 Engedal N, Skotland T, Torgersen ML, Sandvig K. Shiga toxin and its use in targeted cancer therapy and imaging. Microb. Biotechnol.4(1),32–46 (2011).▪▪ Gives an introduction to Shiga toxin and its intracellular transport. Furthermore, an updated overview of the published reports on Gb3 overexpression in human cancers is provided. The possibility of utilizing therapeutic compounds or contrast agents in targeted cancer therapy is discussed.Crossref, Medline, CAS, Google Scholar
70 Farkas-Himsley H, Hill R, Rosen B, Arab S, Lingwood CA. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc. Natl Acad. Sci. USA92(15),6996–7000 (1995).Crossref, Medline, CAS, Google Scholar
71 Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR. The treatment of malignant meningioma with verotoxin. Neoplasia4(4),304–311 (2002).Crossref, Medline, CAS, Google Scholar
72 Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis6(2),129–141 (2003).Crossref, Medline, CAS, Google Scholar
73 Ishitoya S, Kurazono H, Nishiyama H et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J. Urol.171(3),1309–1313 (2004).Crossref, Medline, CAS, Google Scholar
74 Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res.11(1),33–39 (1999).Medline, CAS, Google Scholar
75 Berg K, Folini M, Prasmickaite L et al. Photochemical internalization: a new tool for drug delivery. Curr. Pharm. Biotechnol.8(6),362–372 (2007).Crossref, Medline, CAS, Google Scholar
76 Palermo MS, Exeni RA, Fernandez GC. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev. Anti Infect. Ther.7(6),697–707 (2009).Crossref, Medline, Google Scholar
77 Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther.12(18),1360–1368 (2005).Crossref, Medline, CAS, Google Scholar
78 Noakes KL, Teisserenc HT, Lord JM, Dunbar PR, Cerundolo V, Roberts LM. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett.453(1–2),95–99 (1999).Crossref, Medline, CAS, Google Scholar
79 Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature417(6885),141–147 (2002).Crossref, Medline, Google Scholar
80 Anné J, Maldonado B, Van Impe J, Vanmellaert L, Bernaerts K. Recombinant protein production and streptomycetes. J. Biotechnol.158(4),159–167 (2011).Crossref, Medline, Google Scholar
81 Laureti L, Song L, Huang S et al. Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens. Proc. Natl Acad. Sci. USA108(15),6258–6263 (2011).Crossref, Medline, CAS, Google Scholar
82 Melchior WB Jr, Tolleson WH. A functional quantitative polymerase chain reaction assay for ricin, Shiga toxin, and related ribosome-inactivating proteins. Anal. Biochem.396(2),204–211 (2010).Crossref, Medline, CAS, Google Scholar
83 Risberg K, Fodstad O, Andersson Y. Immunotoxins: a promising treatment modality for metastatic melanoma? Ochsner. J.10(3),193–199 (2010).Medline, Google Scholar
84 Oloomi M, Bouzari S, Shariati E. In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: Assessment of its immunogenicity and toxicity. Iran Biomed. J.14(4),136–141 (2010).Medline, CAS, Google Scholar
85 Stepanov AV, Belogurov AA Jr, Ponomarenko NA et al. Design of targeted B cell killing agents. PLoS One6(6),e20991 (2011).Crossref, Medline, CAS, Google Scholar
86 Vago R, Marsden CJ, Lord JM et al. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J.272(19),4983–4995 (2005).Crossref, Medline, CAS, Google Scholar
87 Delius M, Adams G. Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy. Cancer Res.59(20),5227–5232 (1999).Medline, CAS, Google Scholar
88 Au TK, Collins RA, Lam TL, Ng TB, Fong WP, Wan DC. The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett.471(2–3),169–172 (2000).Crossref, Medline, CAS, Google Scholar
101 Wellcome Trust Sanger Institute. Family: RIP (PF00161). http://pfam.sanger.ac.uk/family/PF00161?acc=PF00161#tabview=tab7Google Scholar
102 Geneious. www.geneious.comGoogle Scholar
103 RSCB Protein Data Bank. Shiga toxin. www.pdb.org/pdb/files/1dm0.pdbGoogle Scholar

Vol. 7, No. 6

Metrics

Downloaded 173 times

History

Published online 18 June 2012

Published in print June 2012

Information

Keywords

Financial & competing interests disclosure

Part of the work on this article was carried out in the framework of an ALFA project II-0313-FA-FCD and CONACYT-Mexico, for which financial support is acknowledged. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download